Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 51

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Prodromal Alzheimer's disease

Not yet recruiting

Efficacy and Safety of Trontinemab with [18F]MK-6240 in Cognitively Unimpaired Individuals at Risk for Alzheimer’s Disease

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Neuromyelitis optica spectrum disorder+7

Not yet recruiting

Safety and dose‑finding study of CD19‑CART01 in patients with SLE, SSc, DM/PM, IMNM, AAV, MG, NMOSD, or chronic GVHD

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico

Glioblastoma

Not yet recruiting

Study of [18F]MC225 PET to Assess Blood‑Brain Barrier Function in Patients with Suspected Glioblastoma

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:[18F]Mc225
  • Sponsor:Universitair Medisch Centrum Groningen

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Ischaemic stroke

Not yet recruiting

Enhanced dual antiplatelet therapy with clopidogrel and acetylsalicylic acid for secondary prevention in patients with mild ischemic stroke

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Technische Universitat Dresden

Parkinson's disease

Not yet recruiting

A Randomized Trial of lu af28996 dh1 to Reduce Motor Fluctuations in Adults with Parkinson’s Disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:H. Lundbeck A/S

Epilepsy

Not yet recruiting

Efficacy of fluoxetine added to standard anti‑seizure therapy in children aged 8 years and older with drug‑resistant complex and rare epilepsy

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Fluoxetine
  • Sponsor:Centre Hospitalier Regional De Marseille

Gaucher's disease type III

Not yet recruiting

Efficacy and safety of oral venglustat versus intravenous imiglucerase in children aged 2‑11 years with Gaucher disease type 3

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Imiglucerase
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Intracranial aneurysm

Not yet recruiting

Comparing two heparin sodium doses on silent brain lesions in patients undergoing embolization of unruptured intracranial aneurysm with drug combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Neurodegenerative disorder

Not yet recruiting

Study of dimethyl fumarate safety and efficacy in patients with Neurodegeneration with Brain Iron Accumulation (NBIA), including PKAN and MPAN

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dimethyl Fumarate
  • Sponsor:Instytut Psychiatrii I Neurologii

Cerebrovascular accident

Not yet recruiting

Effect of baclofen, gabapentin and oxazepam on brain plasticity and motor learning in subacute stroke patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baclofen
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Parkinson's disease

Not yet recruiting

Study of VQ-101 to Slow Progression in Adults with GBA1‑Associated Parkinson’s Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Vanqua Bio Inc.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.